NEJM evidence 2022 Jun 01
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Abstract
Durvalumab Combination for Biliary Tract CancerThis trial randomly assigned patients with previously untreated locally advanced or metastatic biliary tract cancer to receive durvalumab or placebo in combination with gemcitabine plus cisplatin. Median overall survival (95% Cl) was 12.8 (11.1-14.0) months in the durvalumab group. Rates of grade 3 or 4 adverse events were similar between groups.
Related Questions
How do you sequence hypofractionated radiation and systemic therapy for patients with unresectable cholangiocarcinoma?
I have generally cared for patients analogously to that done in the initial NRG GI001 or ABC07 trial designs with the use of initial systemic therapy for 3-6 months followed by consolidative RT targeting a BED > 80.5, assuming a/b ratio of 10 Gy. Tao et al., PMID 26503201 In my practice, it’s most c...
Does ctDNA play a “surveillance” role in advanced biliary tract cancers during active therapy assessing response and/or defining relapsing disease?
I do not routinely measure ctDNA in biliary tract cancers to assess response (I do use tumor markers and a good cross-sectional imaging modality such as CT or MRI, however). The investigators on the TOPAZ-1 study have published their work with ctDNA and it does correlate with responders but it is un...